X-COR Therapeutics: Funding, Investors & Team (Sep 2026)

X-COR Therapeutics is a Boston based medical device company creating the first commercially available CO2 removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR was the runner-up in the 2018 Harvard President’s Innovation Challenge with its device, a novel consumable hybrid cartridge that removes CO2 from patients’ blood with less invasive procedures than high-flow alternatives. X-COR is part of the 2018 MedTech Innovator and MassChallenge cohorts. X-COR’s core technology is a patent-pending medical device that allows physicians to remove excess CO2 from patients who are in symptomatic lung failure and its accompanying control algorithm that is based on machine-learning techniques. The system is compatible with existing medical device infrastructure for ease of use and deployment. Unlike other technologies to treat lung failure, X-COR uses a hybrid approach that allows patients’ blood to be drawn at <300 ml/min flows through small catheters that can be placed by nursing staff. This therapy is more affordable, safer, and more accessible than existing comparable extracorporeal devices that often require >3 L/min flows and highly specialized physicians.

X-COR Therapeutics has raised $2.6M across 1 round on record. The most recent is an undisclosed round of $2.6M announced in Nov 2020.

X-COR Therapeutics' most recent funding round on record is an undisclosed round of $2.6M, announced in Nov 2020.

Jayon Wang is listed as CEO at X-COR Therapeutics.

X-COR Therapeutics is based in Allston, Massachusetts, United States.

X-COR Therapeutics is in the 1-10 employee band.

X-COR Therapeutics' latest round of $2.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.